Physician profile
Suphannee Limprathan
NPI 1487205225
$3,347.32
in general payments reported to CMS, 2019-2025
22 companies · $1,503 in 2025
The $1,503 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.76 · 2022: $233 · 2023: $760 · 2024: $796 · 2025: $1,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128 · Education: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.85 |
| Education | $931.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,164.47 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $327.15 | 2024-2025 | Niktimvo, Monjuvi, Pemazyre |
| Jazz Pharmaceuticals INC. | $236.55 | 2022-2024 | |
| Lilly USA, LLC | $205.56 | 2025 | Verzenio, Jaypirca |
| Astellas Pharma US INC | $197.95 | 2023 | |
| Beigene USA, INC. | $197.73 | 2023-2024 | Brukinsa |
| Celgene Corporation | $150.37 | 2023-2025 | Reblozyl |
| Daiichi Sankyo INC. | $128.31 | 2024-2025 | Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $124.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $99.99 | 2025 | Soliris |
| Rigel Pharmaceuticals, INC. | $72.10 | 2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $66.92 | 2024-2025 | Hyqvia, Livtencity |
| Glaxosmithkline, LLC. | $57.37 | 2025 | Blenrep |
| Gilead Sciences, INC. | $54.76 | 2021 | |
| Geron Corporation | $52.49 | 2025 | Rytelo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $37.53 | 2023 | Adcetris |
| Sobi, INC | $36.21 | 2025 | |
| Legend Biotech USA INC. | $34.27 | 2025 | Carvykti |
| Syndax Pharmaceuticals, INC. | $29.64 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $28.17 | 2025 | Calquence |
| Abbvie INC. | $26.49 | 2025 | |
| Puma Biotechnology, INC. | $18.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suphannee Limprathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.